Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
1.86 (1y: +34%)
Market Cap 105.85 M P/E(ttm)
Enterprise Value 80.49 M P/B 4.92
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry		 vs
history
Cash to Debt 151.083
ATHX's Cash to Debt is ranked higher than
50% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ATHX: 151.083 )
ATHX' s 10-Year Cash to Debt Range
Min: 20.03   Max: No Debt
Current: 151.08
Equity to Asset 0.734
ATHX's Equity to Asset is ranked lower than
75% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 0.54 vs. ATHX: 0.734 )
ATHX' s 10-Year Equity to Asset Range
Min: 0.47   Max: 0.93
Current: 0.73
0.47
0.93
Interest Coverage No Debt
ATHX's Interest Coverage is ranked higher than
81% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ATHX: No Debt )
ATHX' s 10-Year Interest Coverage Range
Min: No Debt   Max: No Debt
Current: No Debt
F-Score: 2
Z-Score: -2.34
M-Score: -2.42
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry		 vs
history
Operating margin (%) -183.80
ATHX's Operating margin (%) is ranked lower than
67% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -52.55 vs. ATHX: -183.80 )
ATHX' s 10-Year Operating margin (%) Range
Min: -1616.4   Max: -128.8
Current: -183.8
-1616.4
-128.8
Net-margin (%) -169.2
ATHX's Net-margin (%) is ranked lower than
66% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -55.70 vs. ATHX: -169.2 )
ATHX' s 10-Year Net-margin (%) Range
Min: -1540.9   Max: -127.3
Current: -169.2
-1540.9
-127.3
ROE (%) -72.8
ATHX's ROE (%) is ranked lower than
79% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -16.60 vs. ATHX: -72.8 )
ATHX' s 10-Year ROE (%) Range
Min: -221.8   Max: -39.7
Current: -72.8
-221.8
-39.7
ROA (%) -53.4
ATHX's ROA (%) is ranked lower than
86% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -14.40 vs. ATHX: -53.4 )
ATHX' s 10-Year ROA (%) Range
Min: -108.7   Max: -36.2
Current: -53.4
-108.7
-36.2
Revenue Growth (%) 35.4
ATHX's Revenue Growth (%) is ranked higher than
92% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. ATHX: 35.4 )
ATHX' s 10-Year Revenue Growth (%) Range
Min: -65.7   Max: 35.4
Current: 35.4
-65.7
35.4
EBITDA Growth (%) -4.3
ATHX's EBITDA Growth (%) is ranked higher than
75% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -11.35 vs. ATHX: -4.3 )
ATHX' s 10-Year EBITDA Growth (%) Range
Min: -71.9   Max: -4.3
Current: -4.3
-71.9
-4.3
EPS Growth (%) -13.7
ATHX's EPS Growth (%) is ranked higher than
72% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -8.70 vs. ATHX: -13.7 )
ATHX' s 10-Year EPS Growth (%) Range
Min: -72   Max: -11.2
Current: -13.7
-72
-11.2
ยป ATHX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

ATHX Guru Trades in Q2 2012

Jean-Marie Eveillard 59,901 sh (New)
» More
Q3 2012

ATHX Guru Trades in Q3 2012

Jean-Marie Eveillard 381,598 sh (+537.05%)
» More
Q4 2012

ATHX Guru Trades in Q4 2012

Jean-Marie Eveillard 4,207,600 sh (+1002.63%)
» More
Q1 2013

ATHX Guru Trades in Q1 2013

Jean-Marie Eveillard 4,207,600 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ATHX

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2012-12-31 Add 1002.63%0.01%$0.95 - $1.33 $ 1.8674%4207600
Jean-Marie Eveillard 2012-09-30 Add 537.05%$1.39 - $1.64 $ 1.8622%381598
Jean-Marie Eveillard 2012-06-30 New Buy$1.28 - $1.65 $ 1.8630%59901
Premium More recent guru trades are included for Premium Members only!!

Ratios

vs
industry		 vs
history
P/B 4.92
ATHX's P/B is ranked lower than
81% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. ATHX: 4.92 )
ATHX' s 10-Year P/B Range
Min: 0.18   Max: 21.64
Current: 4.92
0.18
21.64
P/S 6.00
ATHX's P/S is ranked higher than
61% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 6.90 vs. ATHX: 6.00 )
ATHX' s 10-Year P/S Range
Min: 1.79   Max: 46
Current: 6
1.79
46
EV-to-EBIT -5.03
ATHX's EV-to-EBIT is ranked lower than
54% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 14.61 vs. ATHX: -5.03 )
ATHX' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -5.03

Valuation & Return

vs
industry		 vs
history
Price/Net Cash 5.7
ATHX's Price/Net Cash is ranked lower than
89% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 8.80 vs. ATHX: 5.7 )
ATHX' s 10-Year Price/Net Cash Range
Min: 0.3   Max: 9.1
Current: 5.7
0.3
9.1
Price/Net Current Asset Value 85.7
ATHX's Price/Net Current Asset Value is ranked higher than
89% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 32.60 vs. ATHX: 85.7 )
ATHX' s 10-Year Price/Net Current Asset Value Range
Min: 4.5   Max: 68.8
Current: 85.7
4.5
68.8
Price/Tangible Book 4.8
ATHX's Price/Tangible Book is ranked higher than
92% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 4.70 vs. ATHX: 4.8 )
ATHX' s 10-Year Price/Tangible Book Range
Min: 0.3   Max: 5.6
Current: 4.8
0.3
5.6
Price/Median PS Value 2.4
ATHX's Price/Median PS Value is ranked higher than
64% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: 0.90 vs. ATHX: 2.4 )
ATHX' s 10-Year Price/Median PS Value Range
Min: 0.5   Max: 6.3
Current: 2.4
0.5
6.3
Forward Rate of Return (Yacktman) -53.5
ATHX's Forward Rate of Return (Yacktman) is ranked lower than
97% of the 349 Companies
in the Global Biotechnology industry.

( Industry Median: -4.65 vs. ATHX: -53.5 )
ATHX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -156.4   Max: -21.2
Current: -53.5
-156.4
-21.2

Business Description

Athersys, Inc. was incorporated in Delaware on October 24, 1995. On June 8, 2007, it merged with a wholly owned subsidiary of BTHC VI, Inc., a Delaware corporation, and, on August 31, 2007, BTHC VI, Inc. changed its name to Athersys, Inc. It is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates. The company's current product development portfolio consists of MultiStem, a patented and proprietary stem cell product that it is developing as a treatment for multiple disease indications, and that is currently being evaluated in two ongoing clinical trials. In addition, it is developing pharmaceuticals to treat indications such as obesity, certain cognitive and attention disorders, narcolepsy or other forms of excessive daytime sleepiness. Its business objective is to discover, develop and commercialize novel therapeutic products for disease indications that represent areas of clinical need and commercial opportunity. MultiStem is a biologic product that is manufactured from human stem cells obtained from adult bone marrow or other nonembryonic tissue sources. Potential applications of MultiStem include the treatment of cardiovascular disease, cancer treatment related transplant support, certain neurological conditions, autoimmune disease and other conditions. Factors expressed by MultiStem are believed to reduce inflammation and regulate immune system function, protect damaged or injured cells and tissue, promote formation of new blood vessels, and augment tissue repair and healing in other ways. In its current phase I clinical trial, it is exploring the use of MultiStem as a treatment for damage caused by myocardial infarction, or heart attack. Myocardial infarction is one of the causes of death and disability in the United States. In addition, the Company is developing pharmaceuticals including MultiStem AMI; MultiStem Stroke; and H3 Antagonist cognition to enhance wakefulness and cognitive abilities in individuals suffering from Narcolepsy or Excessive Daytime Sleepiness.
Company Website
SEC Reports
Industry: Biotechnology
Compare:
Traded in other countries:4LS.Germany
ยป More Articles for ATHX

Headlines

Articles On GuruFocus.com
Athersys Inc. (ATHX) CEO Bokkelen Gil Van buys 10,000 Shares Mar 18 2009 

More From Our Partners
Wider-Than-Expected Loss at Athersys - Analyst Blog May 15 2013 - ZACKS

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial